CDA | Evidence Driven
CDA | Evidence Driven

Yervoy for First Line Advanced Melanoma - Details

Details

Files
Generic Name:
Ipilimumab
Project Status:
Complete
Therapeutic Area:
First Line Advanced Melanoma
Manufacturer:
Bristol-Myers Squibb Canada
Brand Name:
Yervoy
Project Line:
Reimbursement Review
Project Number:
PC0042-000
Performance Metric:
N/A — Predated performance metrics
Strength:
5mg/mL
Tumour Type:
Skin and Melanoma
Indications:
First Line Advanced Melanoma
Funding Request:
For the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Bristol-Myers Squibb Canada
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - pERC Final Recommendation Final Recommendation December 22, 2014 View PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - Final Clinical Guidance Report Guidance Reports December 22, 2014 View PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - Final Economic Guidance Report Guidance Reports December 22, 2014 View PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - pERC Initial Recommendation Initial Recommendation December 4, 2014 View PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - PAG Feedback on Initial Recommendation Feedback December 22, 2014 View PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - Manufacturer (Bristol-Myers Squibb Canada) Feedback on Initial Recommendation Feedback December 22, 2014 View PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - Patient Advocacy Group (MNC) Feedback on Initial Recommendation Feedback December 22, 2014 View PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - Patient Advocacy Group (MNC) COI Declarations Feedback December 22, 2014 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : January 15, 2015